NO20075074L - Kinazolinon T-type-kalsiumkanalantagonister - Google Patents
Kinazolinon T-type-kalsiumkanalantagonisterInfo
- Publication number
- NO20075074L NO20075074L NO20075074A NO20075074A NO20075074L NO 20075074 L NO20075074 L NO 20075074L NO 20075074 A NO20075074 A NO 20075074A NO 20075074 A NO20075074 A NO 20075074A NO 20075074 L NO20075074 L NO 20075074L
- Authority
- NO
- Norway
- Prior art keywords
- type calcium
- kinazolinone
- calcium channel
- channel antagonists
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
- C07D239/82—Oxygen atoms with an aryl radical attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65995405P | 2005-03-09 | 2005-03-09 | |
| PCT/US2006/008177 WO2006098969A2 (en) | 2005-03-09 | 2006-03-08 | Quinazolinone t-type calcium channel antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20075074L true NO20075074L (no) | 2007-11-30 |
Family
ID=36992208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20075074A NO20075074L (no) | 2005-03-09 | 2007-10-08 | Kinazolinon T-type-kalsiumkanalantagonister |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7745452B2 (pt) |
| EP (1) | EP1858520B1 (pt) |
| JP (1) | JP2008533020A (pt) |
| KR (1) | KR20070110081A (pt) |
| CN (1) | CN101137380A (pt) |
| AT (1) | ATE527243T1 (pt) |
| AU (1) | AU2006223469A1 (pt) |
| BR (1) | BRPI0608343A2 (pt) |
| CA (1) | CA2600868A1 (pt) |
| IL (1) | IL185391A0 (pt) |
| MX (1) | MX2007010965A (pt) |
| NO (1) | NO20075074L (pt) |
| RU (1) | RU2007137266A (pt) |
| WO (1) | WO2006098969A2 (pt) |
| ZA (1) | ZA200706740B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007010965A (es) * | 2005-03-09 | 2007-09-19 | Merck & Co Inc | Antagonistas de canales de calcio de tipo t de quinazolinona. |
| CA2685753A1 (en) | 2007-05-09 | 2008-11-20 | Neuromed Pharmaceuticals Ltd. | Bicyclic pyrimidine derivatives as calcium channel blockers |
| AU2008275674A1 (en) * | 2007-07-10 | 2009-01-15 | Merck & Co., Inc. | Quinazolinone T-type calcium channel antagonists |
| CA2701203A1 (en) | 2007-10-04 | 2009-04-09 | Merck Sharp & Dohme Corp. | N-substituted oxindoline derivatives as calcium channel blockers |
| JP5470043B2 (ja) * | 2007-10-05 | 2014-04-16 | Ｍｓｄ株式会社 | ベンゾオキサジノン誘導体 |
| WO2010047674A1 (en) | 2008-10-20 | 2010-04-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Low molecular weight thyroid stimulating hormone receptor (tshr) agonists |
| FR2937552B1 (fr) * | 2008-10-27 | 2011-05-06 | Biocodex | Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique |
| JP5965387B2 (ja) | 2010-04-08 | 2016-08-03 | アメリカ合衆国 | Ｔｓｈ受容体用のインバースアゴニストおよびニュートラルアンタゴニスト |
| JP5892550B2 (ja) * | 2010-05-24 | 2016-03-23 | トーアエイヨー株式会社 | 縮合イミダゾール誘導体 |
| RU2650107C2 (ru) * | 2012-09-26 | 2018-04-09 | Мерк Патент Гмбх | Производные хиназолинона в качестве ингибиторов parp |
| WO2015111004A2 (en) * | 2014-01-24 | 2015-07-30 | Discovery Intermediates Private Limited | Improved process for the preparation of chlorophenyl trifluoroethanone |
| US9145388B2 (en) | 2014-02-19 | 2015-09-29 | King Fahd University Of Petroleum And Minerals | 6-piperazinyl-3,4-dihydroquinazolin-2(1H)-ones |
| US9856250B2 (en) | 2014-05-28 | 2018-01-02 | Toa Eiyo Ltd. | Substituted tropane derivatives |
| DK3364993T3 (da) | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| CN106749045B (zh) * | 2017-03-03 | 2020-02-14 | 上海交通大学 | 一种d-氨基酸氧化酶抑制剂及其制法和应用 |
| CN110770221B (zh) * | 2017-04-26 | 2023-09-08 | 卡维昂公司 | 用于改善记忆和认知以及用于治疗记忆和认知障碍的方法 |
| TWI879741B (zh) | 2018-10-03 | 2025-04-11 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
| EP3996746A4 (en) | 2019-07-11 | 2023-08-23 | Praxis Precision Medicines, Inc. | T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF |
| AR127404A1 (es) | 2021-10-20 | 2024-01-17 | Insilico Medicine Ip Ltd | Inhibidores de la metionina adenosiltransferasa 2a (mat2a) y usos de los mismos |
| WO2025255502A1 (en) | 2024-06-07 | 2025-12-11 | Cavion, Inc. | PYRIDYL AMIDE Cav3 CHANNEL MODULATORS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2436792A (en) * | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| IL102764A0 (en) | 1991-08-16 | 1993-01-31 | Merck & Co Inc | Quinazoline derivatives,and pharmaceutical compositions containing them |
| DE4320347A1 (de) * | 1993-06-19 | 1994-12-22 | Boehringer Mannheim Gmbh | Quinazolin-Derivate und diese enthaltende Arzneimittel |
| JP2002505288A (ja) * | 1998-03-02 | 2002-02-19 | コセンシス，インコーポレイテッド | 置換キナゾリンおよびアナログならびにそれらの使用 |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| JP3691341B2 (ja) * | 2000-05-16 | 2005-09-07 | 日新製鋼株式会社 | 精密打抜き性に優れたオーステナイト系ステンレス鋼板 |
| WO2004035000A2 (en) * | 2002-10-17 | 2004-04-29 | Merck & Co., Inc. | Enhancement of sleep with t-type calcium channel antagonists |
| JP4719681B2 (ja) * | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | キナゾリンカリウムチャネル阻害剤 |
| US20070010537A1 (en) * | 2004-08-20 | 2007-01-11 | Kazumasa Hamamura | Fused pyramidine derivative and use thereof |
| MX2007010965A (es) * | 2005-03-09 | 2007-09-19 | Merck & Co Inc | Antagonistas de canales de calcio de tipo t de quinazolinona. |
| CA2573525A1 (en) * | 2006-01-12 | 2007-07-12 | Hitachi, Ltd. | Materials location system and selecting method of materials receiving locations |
-
2006
- 2006-03-08 MX MX2007010965A patent/MX2007010965A/es unknown
- 2006-03-08 JP JP2008500859A patent/JP2008533020A/ja not_active Withdrawn
- 2006-03-08 WO PCT/US2006/008177 patent/WO2006098969A2/en not_active Ceased
- 2006-03-08 CA CA002600868A patent/CA2600868A1/en not_active Abandoned
- 2006-03-08 EP EP06737357A patent/EP1858520B1/en not_active Expired - Lifetime
- 2006-03-08 BR BRPI0608343A patent/BRPI0608343A2/pt not_active IP Right Cessation
- 2006-03-08 KR KR1020077020586A patent/KR20070110081A/ko not_active Withdrawn
- 2006-03-08 US US11/886,053 patent/US7745452B2/en not_active Expired - Lifetime
- 2006-03-08 RU RU2007137266/04A patent/RU2007137266A/ru not_active Application Discontinuation
- 2006-03-08 AU AU2006223469A patent/AU2006223469A1/en not_active Abandoned
- 2006-03-08 AT AT06737357T patent/ATE527243T1/de not_active IP Right Cessation
- 2006-03-08 CN CNA2006800072450A patent/CN101137380A/zh active Pending
-
2007
- 2007-08-14 ZA ZA200706740A patent/ZA200706740B/xx unknown
- 2007-08-20 IL IL185391A patent/IL185391A0/en unknown
- 2007-10-08 NO NO20075074A patent/NO20075074L/no not_active Application Discontinuation
-
2010
- 2010-06-28 US US12/824,702 patent/US20100261741A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007010965A (es) | 2007-09-19 |
| AU2006223469A1 (en) | 2006-09-21 |
| ATE527243T1 (de) | 2011-10-15 |
| US7745452B2 (en) | 2010-06-29 |
| IL185391A0 (en) | 2008-02-09 |
| ZA200706740B (en) | 2008-09-25 |
| EP1858520B1 (en) | 2011-10-05 |
| WO2006098969A3 (en) | 2007-03-01 |
| US20100261741A1 (en) | 2010-10-14 |
| WO2006098969A2 (en) | 2006-09-21 |
| US20080167329A1 (en) | 2008-07-10 |
| EP1858520A4 (en) | 2010-02-10 |
| CN101137380A (zh) | 2008-03-05 |
| KR20070110081A (ko) | 2007-11-15 |
| BRPI0608343A2 (pt) | 2016-10-04 |
| CA2600868A1 (en) | 2006-09-21 |
| RU2007137266A (ru) | 2009-04-20 |
| JP2008533020A (ja) | 2008-08-21 |
| EP1858520A2 (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20075074L (no) | Kinazolinon T-type-kalsiumkanalantagonister | |
| MX2010004530A (es) | Antagonistas de los canales de calcio tipo t de heterociclo fenil amida. | |
| WO2007120729A3 (en) | Pyridyl amide t-type calcium channel antagonists | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| WO2007002884A3 (en) | 4-fluoro-piperidine t-type calcium channel antagonists | |
| DE602007008434D1 (de) | Rezeptoren | |
| EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
| DE602004013563D1 (de) | Rantagonisten | |
| EP1606286A4 (en) | BENZODIAZEPINE SPIROHYDANTOINES AS CGRP RECEPTOR ANTAGONISTS | |
| EA200901166A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr 119 | |
| TW200716546A (en) | Oxindole compounds and their uses as therapeutic agents | |
| CY1110965T1 (el) | Επιπροσθετες ετεροπολυκυκλικες ενωσεις και η χρηση τους ως ανταγωνιστες μεταβολοτροπικου υποδοχεα γλουταμικου | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| WO2008008551A3 (en) | 2-substituted proline bis-amide orexin receptor antagonists | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE516803T1 (de) | Aryl-spirohydantoin-cgrp-rezeptor-antagonisten | |
| MA31451B1 (fr) | Antagonistes des recepteurs de l'orexine de pyridyl piperidine. | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| MX2009010127A (es) | Compuestos utiles como inhibidores de janus cinasas. | |
| EA201170624A1 (ru) | Изоникотинамидные антагонисты рецепторов орексинов | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| TW200724543A (en) | Heterocyclic compounds and their uses as therapeutic agents | |
| WO2007002361A3 (en) | 3-fluoro-piperidine t-type calcium channel antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |